Screening of cognitive impairment in patients with parkinson’s disease: Diagnostic validity of the Brazilian versions of the montreal cognitive assessment and the addenbrooke’s cognitive examination-revised

Abstract

Objective: The aim of the present study is to examine the accuracy of the Brazilian versions of the Montreal Cognitive Assessment (MoCA) and the Addenbrooke’s Cognitive Examination-Revised (ACE-R) to screen for mild cognitive impairment (PDMCI) and dementia (PDD) in patients with Parkinson`s disease (PD). Method: Both scales were administered to a final convenience sample of 79 patients with PD. Patients were evaluated by a neurologist, a psychiatrist and a neuropsychologist using UPDRS, Hoehn and Yahr and Schwab and England scales, global deterioration scale, a psychiatric structured interview, Mattis Dementia Rating Scale and other cognitive tests. Results: There were 32 patients with PDMCI and 17 patients with PDD. The MoCA and the ACE-R were able to discriminate patients with PDD from the others. Conclusion: Both scales showed to be useful to screen for dementia but not for mild cognitive impairment in patients with PD.